Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 15 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral MelanomaRecruitingNCT05789043Phase 3
- Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RDRecruitingNCT05781516Not applicable
- Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）RecruitingNCT05781074Phase 2
- Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationNot yet recruitingNCT05778149Phase 2
- Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionRecruitingNCT05777278Phase 1/2
- A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUCRecruitingNCT05775874Phase 2
- A Study of XZB-0004 in Patients With Solid TumorsRecruitingNCT05772455Phase 1
- Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsRecruitingNCT05771181Phase 2
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.RecruitingNCT05770544Phase 2/3
- DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruitingNCT05770037Phase 2/3
- A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 AlterationsRecruitingNCT05769075Phase 1
- Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsRecruitingNCT05768464Phase 2
- Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung CancerRecruitingNCT05765877Phase 2
- A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaRecruitingNCT05765812Phase 1/2
- Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)RecruitingNCT05762640Phase 2
- Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingNCT05760612Phase 3
- Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingNCT05760378Phase 3
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingNCT05757219Phase 2
- Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GISTRecruitingNCT05751733Not applicable
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
- Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05751018Phase 2
- Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's ArteritisRecruitingNCT05749666Phase 3
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingNCT05748834Phase 2
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingNCT05747729Phase 1/2
- Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerNot yet recruitingNCT05746728Phase 1/2
- Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine TumorsRecruitingNCT05746208Phase 2
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
- Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System TumorsRecruitingNCT05745623Phase 1/2
- Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell CarcinomaRecruitingNCT05738694Phase 3
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingNCT05735184Phase 1
- The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingNCT05728658Phase 1
- Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementRecruitingNCT05727176Phase 2
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataRecruitingNCT05723198Phase 3
- Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma PatientsNot yet recruitingNCT05722977Phase 2
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3
- Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)RecruitingNCT05722795Not applicable
- Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical StudyRecruitingNCT05721651Phase 2
- A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisRecruitingNCT05714072Phase 1
- Alectinib Pharmacokinetic in Patients With NSCLCRecruitingNCT05713006Phase 1/2
- Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerRecruitingNCT05699655Phase 2/3
- Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
- Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus ErythematosusRecruitingNCT05688696Phase 2
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingNCT05687123Phase 1
- Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)RecruitingNCT05686434Phase 2
- Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy SubjectRecruitingNCT05684653Phase 1
- A Study of KC1036 in Patients with Advanced Thymic TumorsRecruitingNCT05683886Phase 2
- A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell MalignanciesRecruitingNCT05683717Phase 1
- Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) LymphomasRecruitingNCT05681195Phase 2
- Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue SarcomaRecruitingNCT05679921Phase 2
- A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT05678270Phase 2
- A Study of TY-1091 in Patients With Advanced Solid TumorsRecruitingNCT05675605Phase 1/2
- Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05675462Phase 1
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingNCT05673928Phase 2
- TT-00973-MS Tablets in Patients With Advanced Solid TumorsNot yet recruitingNCT05673538Phase 1
- A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingNCT05672524Phase 2
- AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular CarcinomaRecruitingNCT05669339Phase 2
- Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCRecruitingNCT05668962Phase 2
- Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLCNot yet recruitingNCT05668767Phase 2
- Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic HepatopathyRecruitingNCT05662813Phase 2
- PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid CancerRecruitingNCT05659186Phase 2
- Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerRecruitingNCT05659056Phase 2
- Advanced or Metastatic CholangiocarcinomaNot yet recruitingNCT05653817Not applicable
- Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older SubjectsRecruitingNCT05653258Phase 2/3
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingNCT05652283Phase 2
- Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior UveitisNot yet recruitingNCT05651880Phase 3
- Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 AlterationsRecruitingNCT05651672Phase 2
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic TumoursRecruitingNCT05644392Phase 1
- Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric CancerNot yet recruitingNCT05643677Phase 2
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingNCT05642572Phase 2
- Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingNCT05638594Phase 2
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingNCT05636514Phase 1
- Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaRecruitingNCT05635162Phase 2
- The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingNCT05634590Phase 2
- A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast CancerNot yet recruitingNCT05621434Phase 2
- Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingNCT05620628Phase 2
- Lenvatinib for Advanced Bone and Soft Tissue SarcomaRecruitingNCT05617859Phase 2
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingNCT05614739Phase 1
- Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT05613894Phase 1
- A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT05613413Phase 2
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingNCT05609630Phase 3
- A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid TumorsNot yet recruitingNCT05609019Phase 1
- Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial CarcinomaRecruitingNCT05603910Phase 1
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaRecruitingNCT05602363Phase 1
- Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT05600660Phase 2
- Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT ModelRecruitingNCT05599256Phase 2
- Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial RemissionNot yet recruitingNCT05596097Phase 2
- Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung CancerNot yet recruitingNCT05595889Phase 2
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic LeukemiaRecruitingNCT05592015Phase 2
- A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaNot yet recruitingNCT05590572Phase 1/2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic CancerRecruitingNCT05580445Phase 1/2
- Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2
- GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast CancerRecruitingNCT05575804Phase 1/2
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
- Masitinib in Patients With Mild Alzheimer's DiseaseNot yet recruitingNCT05564169Phase 3